| Literature DB >> 33841545 |
Mahdieh Hassani1, Maryam Soleimani2, Emran Esmaeilzadeh3, Davood Zare-Abdollahi1, Hamid Reza Khorram Khorshid1.
Abstract
The present study was designed to primarily examine the therapeutic potential of the herbal extract of Melilotus Officinalis for the treatment of multiple sclerosis in the experimental autoimmune encephalomyelitis (EAE) model of the disease. The animal model was induced in C57BL/6 female mice, and then the herbal extract was intraperitoneally administered for a total of 21 days after the first day of post-immunization. The phenotypic signs, a gene expression profile of inflammatory cytokines, antioxidant state, and pathological hallmarks of the disease in the corpus callosum were evaluated. The prophylactic administration of Melilotus Officinalis attenuates the clinical signs of the disease. It significantly declined the gene expression of pro-inflammatory cytokines like IL-6, TNF-α, and IFN-γ. This herbal extract also surged the gene expression, as an anti-inflammatory cytokine. The gene expression of Glutathione peroxidase and Catalase (antioxidant enzymes) was meaningfully higher in the treatment group. Pathological evaluation of corpus callosum cross-sections by Luxol Fast Blue staining revealed preserved myelin sheath in the treated group compared to the EAE mice. The results of our assay confirmed that immunomodulatory and antioxidant features of the herbal extract of Melilotus Officinalis ameliorated the EAE severity. This study finding disclosed the therapeutic efficiency of this compound in MS treatment.Entities:
Keywords: Cytokines; EAE; Melilotus Officinalis; Multiple sclerosis
Year: 2020 PMID: 33841545 PMCID: PMC8019886 DOI: 10.22037/ijpr.2020.113808.14505
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Real time PCR primer sequences
|
|
|
|---|---|
| HPRT-1 | F: AGCCCCAAAATGGTTAAGGT |
| TGF-β | F: CAACAATTCCTGGCGTTACC |
| IL-4 | F: GTCACAGGAGAAGGGACGC |
| IL-5 | F: CCGCCAAAAAGAGAAGTGTG |
| IL-6 | F: ATGATGGATGCTACCAAACTGG |
| IL-12 | F: TGTCGCTAACTCCCTGCATC |
| TNF-α | F: GCCCACGTCGTAGCAAACC |
| IFN-γ | F: TGAGTATTGCCAAGTTTGAGGTC |
| IL-17 | F: GCCCTCAGACTACCTCAACC |
| CAT | F: CAGCCCTGACAAAATGCTTC |
| GPX-1 | F:ATCAGTTCGGACACCAGGAG |
Figure 1Effect of prophylactic administration of Melilotus Officinalis extract on EAE severity and onset (A) The average weight of the mice through evaluation (B) Mean clinical score of groups (C) Grip-strength test data. The results are the means ± SEM of data (***P < 0.001)
Figure 2The effects of Melilotus Officinalis treatment on the cytokines coding gene expression. (*P < 0.05, **P < 0.01, ***P < 0.001). The results are the means ± SEM of data
Figure 3Effects of Melilotus Officinalis treatment on antioxidant status. (A) CAT genes expression, (B) GPX-1 genes expression (C) antioxidant enzyme activity (*P < 0.05, **P < 0.01, ***P < 0.001). The results are the means ± SEM of data
Figure 4Effects of Melilotus Officinalis treatment on the demyelination area in Corpus callosum at different magnifications. Demyelination areas are shown with arrow